A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer
Aim of the study is to evaluate the safety and find the maximal tolerated dose of VB-111 in Patients with Advanced Metastatic Cancer
Advanced and/or Metastatic Solid Organ Cancer
DRUG: VB-111
Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST), 2 months
Nine Cohorts of dose escalating VB-111 were completed with a total of 56 subjects enrolled.